Provided by Tiger Trade Technology Pte. Ltd.

Park Hotels & Resorts Inc.

10.92
+0.08000.74%
Post-market: 10.76-0.1600-1.47%16:08 EST
Volume:5.99M
Turnover:65.41M
Market Cap:2.18B
PE:-163.07
High:11.00
Open:10.80
Low:10.74
Close:10.84
52wk High:15.12
52wk Low:8.27
Shares:199.90M
Float Shares:195.63M
Volume Ratio:1.91
T/O Rate:3.06%
Dividend:1.40
Dividend Rate:12.82%
EPS(TTM):-0.0670
EPS(LYR):1.02
ROE:--
ROA:1.89%
PB:0.65
PE(LYR):10.71

Loading ...

SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D

GlobeNewswire
·
Dec 17

GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GlobeNewswire
·
Dec 11

Park Hotels & Resorts to Sell Three More Non-Core Properties, Reaffirms 2025 Outlook

MT Newswires Live
·
Dec 09

BRIEF-Park Hotels & Resorts Announces The Sale Of Additional Non-Core Hotels

Reuters
·
Dec 09

Park Hotels & Resorts Sells Five Non-Core Hotels for $198 Million

Reuters
·
Dec 09

Park Hotels & Resorts Inc: Reaffirms FY 2025 Outlook With Oct and Prelim Nov Comparable Revpar Results Largely in Line With Expectations

THOMSON REUTERS
·
Dec 09

Park Hotels & Resorts Announces the Sale of Additional Non-Core Hotels and Provides Update on Non-Core Hotel Disposition Activity and Recent Operating Trends

THOMSON REUTERS
·
Dec 09

Three Leading Jiangsu City Commercial Banks Compared: Bank of Jiangsu Leads in Profit, Bank of Nanjing in Revenue Growth, Bank of Suzhou in Risk Control

Deep News
·
Dec 05

Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities

GlobeNewswire
·
Dec 04

Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia

GlobeNewswire
·
Dec 04

Truist Raises Price Target on Park Hotels & Resorts to $12 From $11, Keeps Hold Rating

MT Newswires Live
·
Dec 04

Press Release: Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

Dow Jones
·
Dec 02

Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy

prnewswire
·
Dec 02

Park Hotels & Resorts Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
Dec 01

ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference

GlobeNewswire
·
Dec 01

Akebia Announces Establishment of Rare Kidney Disease Pipeline

GlobeNewswire
·
Dec 01

Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

GlobeNewswire
·
Nov 28

Alphabet vs NVIDIA Ignites Optical Module Sector: Is This the First Step in Rebuilding A-Share Tech Consensus?

Deep News
·
Nov 27

Park Hotels & Resorts (PK): Valuation Insights After Discounted San Francisco Hotel Sales and Portfolio Shift

Simply Wall St.
·
Nov 26

Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS

GlobeNewswire
·
Nov 25